Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in EuropeBusiness Wire • 05/03/21
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for XerostomiaBusiness Wire • 04/30/21
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern TimeBusiness Wire • 04/20/21
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General CounselBusiness Wire • 04/01/21
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from NoriaBusiness Wire • 03/30/21
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021Business Wire • 03/22/21
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal StudiesBusiness Wire • 03/01/21
Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/27/21
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/12/21
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern TimeBusiness Wire • 02/11/21
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual MeetingBusiness Wire • 02/04/21
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.Business Wire • 01/12/21
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging AgentBusiness Wire • 12/09/20
PyL™ (18F-DCFPyL), Lantheus' PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma's PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate CancerBusiness Wire • 12/09/20